Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 5.19 HKD -8.3% Market Closed
Market Cap: 4.2B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Ocumension Therapeutics
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ocumension Therapeutics
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Ocumension Therapeutics
HKEX:1477
Research & Development
-ÂĄ114.8m
CAGR 3-Years
14%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-ÂĄ2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-ÂĄ232.3m
CAGR 3-Years
-31%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-ÂĄ5.8B
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-ÂĄ339.2m
CAGR 3-Years
-19%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Research & Development
-ÂĄ712.5m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
4.2B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Intrinsic Value
4.66 HKD
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Ocumension Therapeutics's Research & Development?
Research & Development
-114.8m CNY

Based on the financial report for Dec 31, 2023, Ocumension Therapeutics's Research & Development amounts to -114.8m CNY.

What is Ocumension Therapeutics's Research & Development growth rate?
Research & Development CAGR 5Y
-23%

Over the last year, the Research & Development growth was 38%. The average annual Research & Development growth rates for Ocumension Therapeutics have been 14% over the past three years , -23% over the past five years .

Back to Top